George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Delighted with the news.seems the inference drawn from the presentation announcement was indeed correct.
I’m not a holder but happy to see this, it’s good for everyone and AIM biotech. Expecting you to see a decent rise today..no pun intended.
Let's hope we have the same uptick in the share price as we did when we got the EU approval of Eroxon.
WAKE UP EVERYONE... see the RNS.
!!!!!!!!
Yee haaa!!!
Try Eroxon to get your rocks off!
Or some variation of:) GLA.
Just a little more titillation about the potential market after FDA approval ( i/we hope)
Here is a link for an Eastern Eroxon advert. (Not sure which country its from) with over 19k views.
https://youtu.be/txEcQHoh7v4
Go to the comments section below video.
Hit the translate to English, button.
The first comment asks " when can we get this"
The YouTubers answer is " waiting for FDA approval"
Seems like there is more hinging on FDA approval than just North America market.
Amazon now reporting 2k + bought in past month. Looks like sales are starting to increase.
Agree with you bh. They are not going to line up these famous people to talk on ED and have to explain why they did not get FDA approval. I think they have the nod and wink from FDA
Some have suggested big pharma could be trying to scupper FDA approval for own self interests but how abt the owners of Boots (American giant Walgreens) actually doing the opposite and being an advocate/pro lobbyist for FUM, the deal being for taking the risk with Boots in the UK they get sole/principal distribution/selling rights in the US. With over 9000 pharmacies/retail outlets boom!! Pure speculation, dreaming or sheer fantasy, maybe the 22nd/26th with the investor conferences will out the reality tho would you really put those shows on if didn't have a good story to tell.
I don't think that we need to be concerned with some reviews on certain UK websites. You can't hold back the tide.The product is clearly selling across European markets and here in the UK. Licenses are in place for many parts of the world and FDA approval round the corner. The current gripes of a few individuals are really going to make no meaningful difference to the long term success or otherwise of FUTURA.
Apologies on spelling previous text, damn predictive text!
Erexon advert on Sky Sport Golf, Volvo Scandanavian Mixed Open.
Amazon stock back up now and they report having sold 1k + in past month. There are some bad reviews but with this many sales if it wasn’t working for the majority there would be far more bad reviews. 8 or so bad reviews amongst over 1000 purchases really isn’t telling the true picture.
Surly FUM would not hold a presentation to attract investment only to announce days later that the FDA had declined to grant approval.
On another note it is becoming increasingly apparent that the Boots site for Eroxon is being manipulated.Compare the reviews for Viagra with the helpful /unhelpful ticks.Some negative reviews for Eroxon attract 80 helpful ticks! This coincides with Liarbooths almost silence on the other BB.
Interesting timing. don't wish to read too much into it, as could have been planned for some time, but i believe fum have stated that they wait until formal FDA minutes of decisions are received rather than RNSing on hearing the informal decisions before minutes, which usually follow the decision about a fortnight later. does this mean they have the informal FDA decision, but are awaiting minutes to advise the market. would be a bit of a disaster PR wise if they had to RNS an FDA rejection on the morning of the presentation! just musing and no firm view.
8 June 2023
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Investor Seminar
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, is
pleased to announce that it will be hosting an Investor Seminar on the 22 June
2023 in London for analysts and institutional investors. Following the
Investor Seminar, an Investor Meet Company meeting will be held for Retail
Investors on Monday the 26 June.
The Investor Seminar follows a milestone year to date following the UK launch
on the 18 April 2023 of MED3000 under the brand name Eroxon® with Cooper
Consumer Health, its EU and UK distribution partner, and online launches in
Europe and in retail pharmacies in Belgium.
The Investor Sseminar will feature presentations from Futura as well as
eminent Key Opinion Leaders (KOLs) Dr Jeff Foster, BSc, (Hons), MB ChB, DRCOG,
MRCGP, men's health specialist and book author and Dr Janine David, FECSM, GP
who specialises in Men and Women's sexual health and will close with a
presentation by Mark Berkhout, International Marketing Director for Cooper
Consumer Health & Jon Connolly Marketing Director Ceuta Healthcare
For further information on the Investor Seminar, or to register your interest,
please contact Optimum Strategic Communications at
futuramedical@optimumcomms.com. Further information will be made available
closer to the event.
A recording will be made available through a webcast which can be accessed via
the investor section of the Futura website shortly after the event. No new
material disclosures will be made at the event.
The Retail Investor event is scheduled for Monday 26 June at 10:00am with
Investor Meet Company. Retail Investors can sign up to Investor Meet Company
for free via www.investormeetcompany.com (http://www.investormeetcompany.com)
.
All the tests and trials undergone by Eroxon returned the same success rate, as you said, over 60%. Those results are monitored and checked. It's very suspicious how Boots 'customers', who aren't controlled or monitored in any way, show a very different result. All you need to drop a negative review on Boots website is an email address, and for people like LiarBOoth and theButler, spare email addresses are ten a penny. You don't even need an email address to give a thumbs up to a bad review, and a thumbs down to a good one, and yet there theButler is on ADVFN going on about how bad the Boots reviews are, in another attempt to bash the stock, which he's been doing for several years. He's even accused 'rampers' of being the people behind the good reviews on Boots! It's a shame that Boots don't seem to worry about it, but I suppose it doesn't really matter to them whether a product fails or not - there's plenty more things for them to sell. Oh well, investing in AIM is never going to be plain sailing!
I’m wondering whether some of those bad reviews are ‘real’. The competitors will be aware of this product and will have organised themselves, I guess. On the other hand all the testing before said would only ‘work’ for ca. 60%. I can empathise with those (real people) who have tried but to no avail.
Amazon currently out of stock, there were some bad reviews some of whom bought from Boots. Wonder if this is due to high demand.
Https://www.medicalnewstoday.com/articles/317090#9
This really would make a significant difference with the approval as you can see
Mention September in full year report for sales update.
Does anyone have a clue when they will bring a trading update on the first month(s) of sales?
Would be Nice to have some knowledge on how first sales are going...
15% up from the low in steady fashion is pleasing. We are getting closer to FDA-day - in the next 3 weeks we will certainly have an update one way or another. Given what is online about FDA decision timeframes, I won't be surprised if there is a further delay, but crossing fingers that isn't the case (and the update is positive!)
I went into my local Boots yesterday ( a sleepy Cotswold town) and it was quiet enough for me to pluck up the courage and ask the female shop assistant, about sales of Eroxon.
She said that it's selling well and that a few days before Boots launched it, men were going in and asking for the product.
GLA roll on FDA approval..